全文获取类型
收费全文 | 1053049篇 |
免费 | 76321篇 |
国内免费 | 1925篇 |
专业分类
耳鼻咽喉 | 14447篇 |
儿科学 | 27484篇 |
妇产科学 | 25532篇 |
基础医学 | 148657篇 |
口腔科学 | 30956篇 |
临床医学 | 92642篇 |
内科学 | 207963篇 |
皮肤病学 | 20827篇 |
神经病学 | 82979篇 |
特种医学 | 41656篇 |
外国民族医学 | 79篇 |
外科学 | 171686篇 |
综合类 | 19804篇 |
现状与发展 | 2篇 |
一般理论 | 400篇 |
预防医学 | 73261篇 |
眼科学 | 23872篇 |
药学 | 81207篇 |
5篇 | |
中国医学 | 2310篇 |
肿瘤学 | 65526篇 |
出版年
2021年 | 7883篇 |
2019年 | 8119篇 |
2018年 | 11606篇 |
2017年 | 8921篇 |
2016年 | 9779篇 |
2015年 | 11333篇 |
2014年 | 15605篇 |
2013年 | 22999篇 |
2012年 | 32058篇 |
2011年 | 33563篇 |
2010年 | 19555篇 |
2009年 | 18627篇 |
2008年 | 32181篇 |
2007年 | 33855篇 |
2006年 | 34284篇 |
2005年 | 33345篇 |
2004年 | 32241篇 |
2003年 | 30757篇 |
2002年 | 30182篇 |
2001年 | 55874篇 |
2000年 | 57467篇 |
1999年 | 48211篇 |
1998年 | 12225篇 |
1997年 | 10664篇 |
1996年 | 10740篇 |
1995年 | 10047篇 |
1994年 | 9226篇 |
1993年 | 8506篇 |
1992年 | 36233篇 |
1991年 | 34676篇 |
1990年 | 33414篇 |
1989年 | 32524篇 |
1988年 | 29679篇 |
1987年 | 28902篇 |
1986年 | 26967篇 |
1985年 | 25898篇 |
1984年 | 18657篇 |
1983年 | 15929篇 |
1982年 | 8835篇 |
1979年 | 16342篇 |
1978年 | 11191篇 |
1977年 | 9595篇 |
1976年 | 8339篇 |
1975年 | 9047篇 |
1974年 | 10879篇 |
1973年 | 10259篇 |
1972年 | 9617篇 |
1971年 | 9132篇 |
1970年 | 8664篇 |
1969年 | 8108篇 |
排序方式: 共有10000条查询结果,搜索用时 453 毫秒
61.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
62.
63.
64.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
65.
66.
67.
Paul J. Devlin Brian W. McCrindle James K. Kirklin Eugene H. Blackstone William M. DeCampli Christopher A. Caldarone Ali Dodge-Khatami Pirooz Eghtesady James M. Meza Peter J. Gruber Kristine J. Guleserian Bahaaladin Alsoufi Linda M. Lambert James E. OBrien Erle H. Austin Jeffrey P. Jacobs Tara Karamlou 《The Journal of thoracic and cardiovascular surgery》2019,157(2):684-695.e8
Objective
Arch obstruction after the Norwood procedure is common and contributes to mortality. We determined the prevalence, associated factors, and practice variability of arch reintervention and assessed whether arch reintervention is associated with mortality.Methods
From 2005 to 2017, 593 neonates in the Congenital Heart Surgeons' Society Critical Left Heart Obstruction cohort underwent a Norwood procedure. Median follow-up was 3.7 years. Multivariable parametric models, including a modulated renewal analysis, were performed.Results
Of the 593 neonates, 146 (25%) underwent 218 reinterventions for arch obstruction after the Norwood procedure: catheter-based (n = 168) or surgical (n = 50) at a median age of 4.3 months (quartile 1-quartile 3, 2.6-5.7). Interdigitation of the distal aortic anastomosis was protective against arch reintervention. Development of ≥ moderate tricuspid valve regurgitation and right ventricular dysfunction at any point was associated with arch reintervention. Nonsignificant variables for arch reintervention included shunt type and preoperative aortic measurements. Surgical arch reintervention was protective against arch reintervention, but transcatheter reintervention was associated with increased reintervention. Arch reintervention was not associated with increased mortality. There was wide institutional variation in incidence of arch reintervention (range, 0-40 reinterventions per 100 years patient follow-up) and in preintervention gradient (range, 0-64 mm Hg).Conclusions
Interdigitation of the distal aortic anastomosis during the Norwood procedure decreased the risk of arch reintervention. Surgical arch reintervention is more definitive than transcatheter. Arch reintervention after the Norwood procedure is not associated with increased mortality. Serial surveillance for arch obstruction, integrated with changes in right ventricular function and tricuspid valve regurgitation, is recommended after the Norwood procedure to improve outcomes. 相似文献68.
69.
70.
Fudaba M. Tachibana D. Misugi T. Nakano A. Koyama M. 《Journal of thrombosis and thrombolysis》2021,51(3):818-820
Journal of Thrombosis and Thrombolysis - Amniotic fluid embolism (AFE) is a catastrophic condition in the peripartum period and still remains as a leading cause of maternal death. Although over 80%... 相似文献